(GEN) Gen Digital - Overview
Stock: Antivirus, Vpn, Identity, Privacy, Utility
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.77% |
| Yield on Cost 5y | 2.59% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 77.2% |
| Payout Ratio | 27.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.6% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -28.14 |
| Character TTM | |
|---|---|
| Beta | 0.890 |
| Beta Downside | 0.991 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.80% |
| CAGR/Max DD | 0.21 |
Description: GEN Gen Digital December 19, 2025
Gen Digital Inc. (NASDAQ: GEN) provides cyber-safety solutions-including security, performance management, identity protection, and online privacy-to consumers, families, and small businesses through the Norton, Avast, LifeLock, MoneyLion, Avira, AVG, and CCleaner brands. The company, formerly NortonLifeLock, rebranded in November 2022 and is headquartered in Tempe, Arizona.
Recent public filings show FY 2023 revenue of roughly **$1.8 billion**, a modest **6 % year-over-year increase** driven primarily by higher subscription renewals in the SMB segment. The firm’s **annual recurring revenue (ARR)** now exceeds **$2.5 billion**, reflecting a shift toward multi-year contracts. A key macro driver is the continued rise in remote-work-induced cyber-risk, which the broader **application-software sector** is seeing as a **CAGR of ~9 %** through 2027 (source: IDC).
Given the competitive landscape and the company’s reliance on brand equity, analysts should monitor **churn rates** (currently estimated at ~12 % for consumer subscriptions) and **integration progress** of recent acquisitions such as MoneyLion, which could materially affect cross-sell opportunities.
For a deeper, data-driven view of GEN’s valuation dynamics, you might explore the analytics platform **ValueRay** to see how its metrics compare across the cyber-security software space.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 570.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -5.60 > 1.0 |
| NWC/Revenue: -28.24% < 20% (prev -67.46%; Δ 39.23% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.32b > Net Income 570.0m |
| Net Debt (8.01b) to EBITDA (2.06b): 3.88 < 3 |
| Current Ratio: 0.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (624.0m) vs 12m ago 0.32% < -2% |
| Gross Margin: 79.32% > 18% (prev 0.80%; Δ 7852 % > 0.5%) |
| Asset Turnover: 28.38% > 50% (prev 24.91%; Δ 3.47% > 0%) |
| Interest Coverage Ratio: 2.78 > 6 (EBITDA TTM 2.06b / Interest Expense TTM 578.0m) |
Altman Z'' 0.40
| A: -0.08 (Total Current Assets 1.29b - Total Current Liabilities 2.55b) / Total Assets 16.05b |
| B: 0.01 (Retained Earnings 217.0m / Total Assets 16.05b) |
| C: 0.10 (EBIT TTM 1.61b / Avg Total Assets 15.76b) |
| D: 0.18 (Book Value of Equity 2.46b / Total Liabilities 13.59b) |
| Altman-Z'' Score: 0.40 = B |
Beneish M -2.54
| DSRI: 1.49 (Receivables 308.0m/178.0m, Revenue 4.47b/3.85b) |
| GMI: 1.01 (GM 79.32% / 80.38%) |
| AQI: 1.00 (AQ_t 0.92 / AQ_t-1 0.91) |
| SGI: 1.16 (Revenue 4.47b / 3.85b) |
| TATA: -0.05 (NI 570.0m - CFO 1.32b) / TA 16.05b) |
| Beneish M-Score: -2.54 (Cap -4..+1) = A |
What is the price of GEN shares?
Over the past week, the price has changed by -7.18%, over one month by -8.75%, over three months by -9.05% and over the past year by -10.33%.
Is GEN a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.9 | 38.1% |
| Analysts Target Price | 32.9 | 38.1% |
| ValueRay Target Price | 24.8 | 4.3% |
GEN Fundamental Data Overview February 03, 2026
P/E Forward = 8.5324
P/S = 3.3076
P/B = 6.0266
P/EG = 0.9035
Revenue TTM = 4.47b USD
EBIT TTM = 1.61b USD
EBITDA TTM = 2.06b USD
Long Term Debt = 8.42b USD (from longTermDebt, last quarter)
Short Term Debt = 280.0m USD (from shortTermDebt, last quarter)
Debt = 8.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.01b USD (from netDebt column, last quarter)
Enterprise Value = 22.81b USD (14.80b + Debt 8.70b - CCE 691.0m)
Interest Coverage Ratio = 2.78 (Ebit TTM 1.61b / Interest Expense TTM 578.0m)
EV/FCF = 17.54x (Enterprise Value 22.81b / FCF TTM 1.30b)
FCF Yield = 5.70% (FCF TTM 1.30b / Enterprise Value 22.81b)
FCF Margin = 29.06% (FCF TTM 1.30b / Revenue TTM 4.47b)
Net Margin = 12.74% (Net Income TTM 570.0m / Revenue TTM 4.47b)
Gross Margin = 79.32% ((Revenue TTM 4.47b - Cost of Revenue TTM 925.0m) / Revenue TTM)
Gross Margin QoQ = 78.20% (prev 78.76%)
Tobins Q-Ratio = 1.42 (Enterprise Value 22.81b / Total Assets 16.05b)
Interest Expense / Debt = 1.68% (Interest Expense 146.0m / Debt 8.70b)
Taxrate = 42.49% (99.0m / 233.0m)
NOPAT = 923.6m (EBIT 1.61b * (1 - 42.49%))
Current Ratio = 0.51 (Total Current Assets 1.29b / Total Current Liabilities 2.55b)
Debt / Equity = 3.54 (Debt 8.70b / totalStockholderEquity, last quarter 2.46b)
Debt / EBITDA = 3.88 (Net Debt 8.01b / EBITDA 2.06b)
Debt / FCF = 6.16 (Net Debt 8.01b / FCF TTM 1.30b)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.62% (Net Income 570.0m / Total Assets 16.05b)
RoE = 24.67% (Net Income TTM 570.0m / Total Stockholder Equity 2.31b)
RoCE = 14.97% (EBIT 1.61b / Capital Employed (Equity 2.31b + L.T.Debt 8.42b))
RoIC = 8.49% (NOPAT 923.6m / Invested Capital 10.89b)
WACC = 6.14% (E(14.80b)/V(23.50b) * Re(9.19%) + D(8.70b)/V(23.50b) * Rd(1.68%) * (1-Tc(0.42)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.64%
[DCF Debug] Terminal Value 85.69% ; FCFF base≈1.63b ; Y1≈1.69b ; Y5≈1.92b
Fair Price DCF = 72.33 (EV 52.61b - Net Debt 8.01b = Equity 44.60b / Shares 616.7m; r=6.14% [WACC]; 5y FCF grow 3.71% → 2.90% )
EPS Correlation: 94.88 | EPS CAGR: 9.58% | SUE: 0.67 | # QB: 0
Revenue Correlation: 90.80 | Revenue CAGR: 15.88% | SUE: 0.96 | # QB: 3
EPS next Year (2027-03-31): EPS=2.86 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+12.5% | Growth Revenue=+4.7%